Table 1

Summary of potential novel therapeutic options and biologics for SLE
Drug name Target Study participants Mechanism of action Trials
Rituximab Chimeric anti-CD20 monoclonal antibody 257 SLE patients with moderately-to-severely active disease ( ≥1 BILAG A score or ≥2 BILAG B scores) B cell apoptosis or lysis Explorer
144 patients with class III or class IV lupus nephritis Lunar
Belimumab Humanized anti-BLyS monoclonal antibody 865 seropositive SLE patients with SELENA-SLEDAI score ≥6. Severe active lupus nephritis and severe CNS disease excluded. BLyS inhibition blocks soluble BLys and prevents binding to B cell receptor Bliss-52
819 seropositive SLE patients with SELENA-SLEDAI score ≥6. Severe active lupus nephritis & severe CNS disease excluded. Bliss-76
Blisibimod Anti-BLyS antagonist fusion protein Active SLE BLyS inhibition blocks soluble BLys and prevents binding to B cell receptor Pearl-sc
Atacicept Recombinant fusion protein to TACI-Ig SLE excluding lupus nephritis. Inhibition of B cell activation by BLys and APRIL Phase II/III
Lupus nephritis study discontinued due to reports of increased infection.
Epratuzumab Humanized anti-CD22 monoclonal antibody 227 moderate to severe SLE patients. B cell apoptosis Emblem
Moderate to severe SLE patients excluding severe renal and neuropsychiatric disease. Embody
Abatacept CTL4-Ig fusion protein SLE with polyarthritis, discoid lesions, or pleuritis and/or pericarditis. Blockade of co-stimulatory interaction of T and B lymphocytes Phase III
Data reanalyzed for lupus nephritis
Tocilizumab Humanized anti-IL6 receptor monoclonal antibody SLE patients with mild-to-moderate disease activity. Inhibition of membrane bound and soluble IL-6 receptor Phase I
Sifalimumab Humanized anti-IFNα monoclonal antibody Moderately active SLE. Inhibition of type I IFN signature Phase II
Rontalizumab A recombinant humanized monoclonal antibody to IFN-α Moderate to severe non-renal SLE

Jordan et al.

Jordan et al. BMC Medicine 2013 11:120   doi:10.1186/1741-7015-11-120

Open Data